Display options
Cite
Ahmad F, Shankar EM, Yong YK, et al. Negative Checkpoint Regulatory Molecule 2B4 (CD244) Upregulation Is Associated with Invariant Natural Killer T Cell Alterations and Human Immunodeficiency Virus Disease Progression. Front Immunol. 2017;8:338doi: 10.3389/fimmu.2017.00338.
Ahmad, F., Shankar, E. M., Yong, Y. K., Tan, H. Y., Ahrenstorf, G., Jacobs, R., Larsson, M., Schmidt, R. E., Kamarulzaman, A., & Ansari, A. W. (2017). Negative Checkpoint Regulatory Molecule 2B4 (CD244) Upregulation Is Associated with Invariant Natural Killer T Cell Alterations and Human Immunodeficiency Virus Disease Progression. Frontiers in immunology, 8338. https://doi.org/10.3389/fimmu.2017.00338
Ahmad, Fareed, et al. "Negative Checkpoint Regulatory Molecule 2B4 (CD244) Upregulation Is Associated with Invariant Natural Killer T Cell Alterations and Human Immunodeficiency Virus Disease Progression." Frontiers in immunology vol. 8 (2017): 338. doi: https://doi.org/10.3389/fimmu.2017.00338
Ahmad F, Shankar EM, Yong YK, Tan HY, Ahrenstorf G, Jacobs R, Larsson M, Schmidt RE, Kamarulzaman A, Ansari AW. Negative Checkpoint Regulatory Molecule 2B4 (CD244) Upregulation Is Associated with Invariant Natural Killer T Cell Alterations and Human Immunodeficiency Virus Disease Progression. Front Immunol. 2017 Mar 27;8:338. doi: 10.3389/fimmu.2017.00338. eCollection 2017. PMID: 28396665; PMCID: PMC5366318.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2017 Mar 27;8:338. doi: 10.3389/fimmu.2017.00338. eCollection 2017.

Negative Checkpoint Regulatory Molecule 2B4 (CD244) Upregulation Is Associated with Invariant Natural Killer T Cell Alterations and Human Immunodeficiency Virus Disease Progression.

Frontiers in immunology

Fareed Ahmad, Esaki M Shankar, Yean K Yong, Hong Y Tan, Gerrit Ahrenstorf, Roland Jacobs, Marie Larsson, Reinhold E Schmidt, Adeeba Kamarulzaman, Abdul W Ansari

Affiliations

  1. Department of Clinical Immunology and Rheumatology, Hannover Medical School , Hannover , Germany.
  2. Centre of Excellence for Research in AIDS (CERiA), University of Malaya, Kuala Lumpur, Malaysia; Department of Medical Microbiology, University of Malaya, Kuala Lumpur, Malaysia; Division of Infection Biology, Department of Life Sciences, School of Basic & Applied Sciences, Central University of Tamil Nadu (CUTN), Thiruvarur, India.
  3. Centre of Excellence for Research in AIDS (CERiA), University of Malaya , Kuala Lumpur , Malaysia.
  4. Division of Molecular Virology, Department of Clinical and Experimental Medicine, Linkoping University , Linkoping , Sweden.
  5. Centre of Excellence for Research in AIDS (CERiA), University of Malaya, Kuala Lumpur, Malaysia; Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

PMID: 28396665 PMCID: PMC5366318 DOI: 10.3389/fimmu.2017.00338

Abstract

The CD1d-restricted invariant natural killer T (iNKT) cells are implicated in innate immune responses against human immunodeficiency virus (HIV). However, the determinants of cellular dysfunction across the iNKT cells subsets are seldom defined in HIV disease. Herein, we provide evidence for the involvement of the negative checkpoint regulator (NCR) 2B4 in iNKT cell alteration in a well-defined cohort of HIV-seropositive anti-retroviral therapy (ART) naïve, ART-treated, and elite controllers (ECs). We report on exaggerated 2B4 expression on iNKT cells of HIV-infected treatment-naïve individuals. In sharp contrast to CD4

Keywords: 2B4; CD4; IFN-γ; human immunodeficiency virus; inhibitory; invariant natural killer T cells

References

  1. Scand J Immunol. 2011 Oct;74(4):406-11 - PubMed
  2. J Immunol. 2010 Jul 15;185(2):877-83 - PubMed
  3. PLoS Pathog. 2016 Jul 14;12(7):e1005761 - PubMed
  4. Immunology. 2003 Jan;108(1):1-2 - PubMed
  5. Mol Immunol. 2000 Jun;37(9):493-501 - PubMed
  6. J Exp Med. 2006 Oct 2;203(10):2281-92 - PubMed
  7. Nat Rev Immunol. 2012 Dec;12(12):845-57 - PubMed
  8. Biochem Biophys Res Commun. 2011 Feb 18;405(3):503-7 - PubMed
  9. Blood. 2005 Jun 15;105(12 ):4722-9 - PubMed
  10. AIDS Res Hum Retroviruses. 2007 Jul;23(7):913-22 - PubMed
  11. Nat Immunol. 2009 Jan;10(1):29-37 - PubMed
  12. J Exp Med. 2002 Mar 4;195(5):625-36 - PubMed
  13. J Immunol. 2008 Jun 15;180(12 ):8159-67 - PubMed
  14. J Virol. 2014 Nov;88(21):12397-408 - PubMed
  15. J Exp Med. 2002 Apr 1;195(7):869-79 - PubMed
  16. Immunol Cell Biol. 2014 Aug;92(7):578-90 - PubMed
  17. Eur J Immunol. 2009 Mar;39(3):902-11 - PubMed
  18. J Exp Med. 2002 Mar 4;195(5):637-41 - PubMed
  19. Int Immunol. 2007 Aug;19(8):943-51 - PubMed
  20. J Immunol. 2006 Nov 1;177(9):5775-8 - PubMed
  21. PLoS Pathog. 2012;8(8):e1002838 - PubMed
  22. Nature. 2009 Mar 12;458(7235):206-10 - PubMed
  23. J Virol. 2008 Apr;82(7):3391-404 - PubMed
  24. AIDS. 2016 Jul 17;30(11):1713-22 - PubMed
  25. Blood. 2011 May 5;117(18):4805-15 - PubMed
  26. Eur J Immunol. 1999 May;29(5):1676-83 - PubMed
  27. PLoS Pathog. 2011 May;7(5):e1002045 - PubMed
  28. Immunology. 2003 Jan;108(1):3-9 - PubMed
  29. AIDS. 2009 Sep 24;23(15):1965-70 - PubMed
  30. Nature. 2006 Sep 21;443(7109):350-4 - PubMed
  31. Immunity. 2007 Oct;27(4):670-84 - PubMed
  32. Immunology. 2007 Sep;122(1):1-14 - PubMed
  33. J Virol. 2002 Aug;76(15):7528-34 - PubMed
  34. Curr HIV/AIDS Rep. 2011 Mar;8(1):4-11 - PubMed
  35. J Immunol. 2013 Sep 1;191(5):2072-81 - PubMed
  36. Blood. 2006 Apr 15;107(8):3081-3 - PubMed
  37. Nat Med. 2006 Oct;12(10):1198-202 - PubMed
  38. Retrovirology. 2013 Mar 20;10:31 - PubMed
  39. Annu Rev Immunol. 2007;25:297-336 - PubMed
  40. AIDS Res Hum Retroviruses. 2011 Jan;27(1):1-3 - PubMed
  41. Int Immunol. 2006 Oct;18(10):1443-51 - PubMed
  42. Hepatology. 2010 Dec;52(6):1934-47 - PubMed
  43. J Clin Invest. 2010 Jun;120(6):1925-38 - PubMed
  44. J Immunol. 2002 Feb 1;168(3):1490-5 - PubMed
  45. Blood. 2002 Jul 1;100(1):11-6 - PubMed
  46. Eur J Immunol. 2007 Jan;37(1):193-8 - PubMed
  47. J Exp Med. 1998 Dec 7;188(11):2083-90 - PubMed
  48. Front Immunol. 2012 Dec 11;3:377 - PubMed

Publication Types